Brind.
  1. Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation.
  2. Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.

Natera's Signatera Test Integrated into Phase III Breast Cancer Trial

1 report, 1 independent Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Alliance Foundation Trials, LLC (AFT) launched AFT-70 NAVIGATE, a randomized Phase III clinical trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer. The trial pairs giredestrant with longitudinal Signatera Genome MRD monitoring to identify patients who may benefit from treatment escalation with a CDK4/6 inhibitor. The trial is sponsored and led by AFT, with collaboration and co-funding from Natera and Genentech, a member of the Roche Group.

From news-medical.net

Why it matters

Some supportBrind's analysis of the reports

The trial tests a strategy to improve outcomes in early breast cancer by selectively escalating therapy based on monitoring results. This work supports the potential for giredestrant to provide a meaningful improvement in invasive disease-free survival when combined with the monitoring strategy.

Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by Alliance Foundation Trials, LLC.

From news-medical.net

Who's involved

  • NateraProvider of the Signatera technology used for longitudinal MRD monitoring in the trial.
  • Hoffmann-La RocheCo-funder of the trial and utilizes Genentech technology in the evaluation.
  • Alliance Foundation TrialsLeader and sponsor of the AFT-70 NAVIGATE Phase III clinical trial.

Keep exploring

Part of

Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation. All 2 developments

Within Natera uses Panorama for non-invasive prenatal testing and faces intellectual property litigation.

The entities involved

Related events

Coverage

Newest first; wire copies grouped